Grade 3a Follicular Lymphoma Clinical Trial
Official title:
Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma
Verified date | June 2024 |
Source | University of Washington |
Contact | Ajay Gopal |
Phone | 206-606-2037 |
agopal[@]uw.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | February 12, 2027 |
Est. primary completion date | August 12, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older at time of signing informed consent - Capable of understanding and providing written informed consent - Histologically confirmed indolent B-cell non-Hodgkin lymphoma with no prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are allowed.) Eligible histologies include: - Follicular lymphoma (grade 1-2 or 3A) - Marginal zone lymphoma - Ann Arbor stage II-IV disease - No prior therapy for lymphoma - Have low-tumor burden disease, defined by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria: - Nodal or extranodal tumor mass < 7 cm - Involvement of less than 3 nodal sites with a diameter > 3 cm - No systemic or B symptoms - No splenomegaly > 16 cm by imaging - No local risk of vital organ compression - No pleural or peritoneal serous effusions - No leukemic phase (> 5,0000/ uL circulating lymphocytes) - No significant cytopenias defined as platelets < 100,000/uL, hemoglobin < 10 g/dL, or absolute neutrophil count (ANC) < 1500/ uL - Have measurable nodal disease, including at least 1 disease site measuring at least 1.5 cm in longest dimension on CT or fludeoxyglucose F-18 (FDG)-PET, or a FDG-avid extranodal measurable site measuring at least 1.0 cm in longest dimension. Measurable disease also includes spleen size more than 13 cm in vertical length - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Creatinine clearance = 50 mL/min calculated by Cockcroft-Gault equation - Total bilirubin = 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome who may have a total bilirubin up to = 3 x ULN - Aspartate aminotransferase (AST) = 3 x the ULN - Alanine aminotransferase (ALT) = 3 x the ULN - Gamma glutamyl transferase (GGT) = 3 x the ULN - Negative serum or urine pregnancy test within 7 days of initiating mosunetuzumab for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year - Fertile male and woman of childbearing potential must agree to use highly effective contraceptive methods from start of treatment to at least 3 months after the last dose of mosunetuzumab Exclusion Criteria: - History of severe allergic reaction to monoclonal antibody therapy - History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the principal investigator (PI) may be included - Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection at study enrollment - Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count = 200) - Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HbBsAg] serology): - Patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening. These patients must be willing to undergo monthly DNA testing and appropriate antiviral therapy as indicated by institutional standards - Autoimmune disease requiring active therapy - History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) - Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm) - Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent - Prior use of any monoclonal antibody within 4 weeks before the first mosunetuzumab administration - Prior solid organ transplantation - Pregnant or breast-feeding women, or intending to become pregnant during the study or within 3 months of the last dose of mosunetuzumab |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall response (OR) | OR will be defined as complete response and partial response at the end of therapy based on the latest version of Lugano criteria. Response rates will be calculated using simple binomial proportions and the corresponding 95% confidence interval will be derived. | Up to week 13 | |
Secondary | Incidence of adverse events (AE's) | All AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. AEs will be summarized by type, severity, duration, and attribution. | Up to 30 days after last dose of study treatment | |
Secondary | Incidence of grade 3 or greater cytokine release syndrome (CRS) | CRS will be graded by the American Society for Transplantation and Cellular Therapy Consensus Grading system. | Up to 30 days after last dose of study treatment | |
Secondary | Incidence of Immune Effector Cell Associated Neurotoxicity syndrome | Up to 30 days after last dose of study treatment | ||
Secondary | Progression free survival (PFS) | Kaplan-Meier methodology will be used to estimate PFS. | At initiation of study treatment to disease progression, up to 5 years | |
Secondary | Duration of response | Up to 5 years | ||
Secondary | Time to next lymphoma treatment | Kaplan-Meier methodology will be used to estimate time to next lymphoma treatment. | At initiation of study treatment to initiation of next therapy, up to 5 years | |
Secondary | Time to cytotoxic treatment | Kaplan-Meier methodology will be used to estimate time to cytotoxic treatment. | At initiation of study treatment to initiation of cytotoxic treatment, up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04883437 -
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
|
Phase 2 | |
Completed |
NCT02927964 -
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01995669 -
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05169658 -
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT03010358 -
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04404088 -
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
|
Phase 2 | |
Recruiting |
NCT03269669 -
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT02950220 -
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT04450173 -
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT02992522 -
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT03198026 -
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
|
Phase 2 | |
Active, not recruiting |
NCT03015896 -
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02871219 -
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
|
Phase 2 | |
Recruiting |
NCT04257578 -
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03410901 -
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT01286272 -
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT01849263 -
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT02532257 -
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
|
Phase 2 |